UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 131

Sortiert nach

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis

Annals of oncology, 2012-10, Vol.23 (10), p.2656-2662

2012

Link zum Volltext

Verfügbarkeit prüfen

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma

Annals of oncology, 2021-05, Vol.32 (5), p.609-619

2021

Link zum Volltext

Verfügbarkeit prüfen

Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trial

Annals of oncology, 2018-12, Vol.29 (12), p.2393-2395

2018

Link zum Volltext

Verfügbarkeit prüfen

A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology

ESMO open, 2023-10, Vol.8 (5), p.101623-101623, Article 101623

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas

Annals of oncology, 2011-08, Vol.22 (8), p.1839-1844

2011

Link zum Volltext

Verfügbarkeit prüfen

“The German- Registry” of incidental gallbladder cancer and the GAIN - phase III trial: Transformation from a registry to treatment platform due to a trial in trial concept

Annals of oncology, 2018-10, Vol.29, p.viii263-viii263

2018

Link zum Volltext

Verfügbarkeit prüfen

New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma

Journal of cellular and molecular medicine, 2008-12, Vol.12 (6a), p.2457-2466

2008

Link zum Volltext

Verfügbarkeit prüfen

Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine (nab-P/G) vs FOLFIRINOX (FFX) in patients (pts) with advanced pancreatic cancer (aPC)

Annals of oncology, 2018-10, Vol.29, p.viii245-viii246

2018

Link zum Volltext

Verfügbarkeit prüfen

Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Annals of oncology, 2009-03, Vol.20 (3), p.481-485

2009

Link zum Volltext

Verfügbarkeit prüfen

Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): The randomized phase II INTEGA trial (AIO STO 0217)

Annals of oncology, 2018-10, Vol.29, p.viii265-viii266

2018

Link zum Volltext

Verfügbarkeit prüfen

Association of microRNA-21 (miR-21) with efficacy of cetuximab (cet) and bevacizumab (bev) in patients with metastatic colorectal cancer (mCRC) within the FIRE-3 study (AIO KRK-0306)

Annals of oncology, 2018-10, Vol.29, p.viii39-viii39

2018

Link zum Volltext

Verfügbarkeit prüfen

Quality of life (QoL) in patients with metastatic pancreatic cancer receiving first-line Nab-paclitaxel/gemcitabine chemotherapy: Results of the large QoL study AIO-QoliXane/PARAGON

Annals of oncology, 2018-10, Vol.29, p.viii252-viii252

2018

Link zum Volltext

Verfügbarkeit prüfen

Independent Radiological Evaluation of Objective Response Early Tumor Shrinkage, and Depth of Response in FIRE-3 (AIO KRK-0306)

Annals of oncology, 2014-06, Vol.25, p.ii117-ii117

2014

Link zum Volltext

Verfügbarkeit prüfen

Vom „Stiefkind“ zum Paradebeispiel

Der Onkologe, 2013-05, Vol.19 (5), p.350-351

2013

Link zum Volltext

Verfügbarkeit prüfen

Behandlungsalgorithmen für Adenokarzinome des Magens oder ösophagogastralen Übergangs

Der Onkologe, 2013-05, Vol.19 (5), p.352-353

2013

Link zum Volltext

Verfügbarkeit prüfen

Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study

European journal of cancer (1990), 2020-03, Vol.127, p.150-157

2020

Link zum Volltext

Verfügbarkeit prüfen

Prognostic factors in curative treatment of gallbladder cancer - Data of 950 cases of “The German- Registry”

Annals of oncology, 2016-10, Vol.27, p.vi210-vi210

2016

Link zum Volltext

Verfügbarkeit prüfen

Multimodale Therapie des lokalisierten Magenkarzinoms

Der Onkologe, 2016-06, Vol.22 (6), p.392-399

2016

Link zum Volltext

Verfügbarkeit prüfen

A phase I trial of the trifunctional anti Her2 x anti CD3 antibody ertumaxomab in patients with advanced solid tumors

BMC cancer, 2016-07, Vol.16 (1)

2016

Link zum Volltext

Verfügbarkeit prüfen

Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial

British journal of cancer, 2007-07, Vol.97 (2), p.177-182

2007

Link zum Volltext

Verfügbarkeit prüfen

195TiP GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)

Annals of oncology, 2020-11, Vol.31, p.S1315-S1316

2020

Link zum Volltext

Verfügbarkeit prüfen

Algorithmus zur Therapie des Magenkarzinoms

Der Onkologe, 2016-06, Vol.22 (6), p.368-370

2016

Link zum Volltext

Verfügbarkeit prüfen

Association of disease measurability, quality of life (QoL) and tumor status in patients (pts) with previously treated advanced gastric or gastroesophageal junction (GEJ) cancer

Annals of oncology, 2016-10, Vol.27, p.vi215-vi215

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 131

Suche als RSS-Feed

Aktive Filter

ThemaAged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(121)
Mit Volltextzugriff
(122)

Publikationsform

Sprache

Englisch
(115)
Deutsch
(16)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Oncology
(21)
Life Sciences & Biomedicine
(19)
Science & Technology
(19)
Humans
(15)
Gastric Cancer
(7)
Tumors
(7)
Antineoplastic Agents
(6)
Biological And Medical Sciences
(6)
Male
(6)
Medical Sciences
(6)
Medicine
(6)
Medicine & Public Health
(6)
Female
(5)
Pharmacology. Drug Treatments
(5)
Prognosis
(4)
Treatment Outcome
(4)
Adult
(3)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(3)
Esophageal Neoplasms - Drug Therapy
(3)
Gastroenterology. Liver. Pancreas. Abdomen
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma

Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trial

A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology

Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas

“The German- Registry” of incidental gallbladder cancer and the GAIN - phase III trial: Transformation from a registry to treatment platform due to a trial in trial concept

New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma

Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine (nab-P/G) vs FOLFIRINOX (FFX) in patients (pts) with advanced pancreatic cancer (aPC)

Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): The randomized phase II INTEGA trial (AIO STO 0217)

Quality-of-life (QoL) results from RAINFALL: A randomized, double-blind, placebo (PL)-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy for metastatic gastric or gastroesophageal junction (G-GEJ) cancer

Association of microRNA-21 (miR-21) with efficacy of cetuximab (cet) and bevacizumab (bev) in patients with metastatic colorectal cancer (mCRC) within the FIRE-3 study (AIO KRK-0306)

Quality of life (QoL) in patients with metastatic pancreatic cancer receiving first-line Nab-paclitaxel/gemcitabine chemotherapy: Results of the large QoL study AIO-QoliXane/PARAGON

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

Independent Radiological Evaluation of Objective Response Early Tumor Shrinkage, and Depth of Response in FIRE-3 (AIO KRK-0306)

Vom „Stiefkind“ zum Paradebeispiel

Behandlungsalgorithmen für Adenokarzinome des Magens oder ösophagogastralen Übergangs

Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study

Prognostic factors in curative treatment of gallbladder cancer - Data of 950 cases of “The German- Registry”

Multimodale Therapie des lokalisierten Magenkarzinoms

A phase I trial of the trifunctional anti Her2 x anti CD3 antibody ertumaxomab in patients with advanced solid tumors

Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial

195TiP GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)

Algorithmus zur Therapie des Magenkarzinoms

Association of disease measurability, quality of life (QoL) and tumor status in patients (pts) with previously treated advanced gastric or gastroesophageal junction (GEJ) cancer

Aktive Filter

Suchergebnisse filtern